Seelos Therapeutics, Inc.: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Seelos Therapeutics, Inc. listata cu simbolul US.SEEL ==Descriere companie== Seelos Therapeutics, Inc. (https://seelostherapeutics.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company’s lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disor...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Seelos Therapeutics, Inc. (https://seelostherapeutics.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company’s lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company’s ongoing programs include SLS-004, SLS-006, SLS-007, and SLS-008. | Seelos Therapeutics, Inc. (https://seelostherapeutics.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in [[CENTRAL|central]] nervous system (CNS) disorders and other rare disorders. The Company’s lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company’s ongoing programs include SLS-004, SLS-006, SLS-007, and SLS-008. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 3 octombrie 2024 08:47
Pagina dedicata companiei Seelos Therapeutics, Inc. listata cu simbolul US.SEEL
Descriere companie[edit | ]
Seelos Therapeutics, Inc. (https://seelostherapeutics.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company’s lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company’s ongoing programs include SLS-004, SLS-006, SLS-007, and SLS-008.
Grafic actiuni companie[edit | ]